European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
Language English Country Switzerland Media print-electronic
Document type Journal Article, Practice Guideline
PubMed
26188393
DOI
10.1016/j.eururo.2015.06.044
PII: S0302-2838(15)00550-3
Knihovny.cz E-resources
- Keywords
- Cytology, Guidelines, Nephroureterectomy, Renal pelvis, Risk factors, Survival, Ureter, Ureteroscopy, Urinary tract cancer, Urothelial carcinoma,
- MeSH
- Chemotherapy, Adjuvant MeSH
- Administration, Intravesical MeSH
- Carcinoma, Transitional Cell diagnosis therapy MeSH
- Kidney Pelvis pathology MeSH
- Humans MeSH
- Neoplasm Recurrence, Local prevention & control MeSH
- Mitomycin therapeutic use MeSH
- Kidney Neoplasms diagnosis therapy MeSH
- Urinary Bladder Neoplasms prevention & control MeSH
- Ureteral Neoplasms diagnosis therapy MeSH
- Nephrectomy * MeSH
- Antibiotics, Antineoplastic therapeutic use MeSH
- Societies, Medical MeSH
- Ureter surgery MeSH
- Ureteroscopy MeSH
- Urology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Names of Substances
- Mitomycin MeSH
- Antibiotics, Antineoplastic MeSH
CONTEXT: The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
Department of Radiology Queen Alexandra Hospital Portsmouth UK
Department of Surgery Hyvinkää Hospital Hyvinkää Finland
Department of Urology Caritas St Josef Medical Centre University of Regensburg Regensburg Germany
Department of Urology Medizinische Universität Graz Graz Austria
Department of Urology Universitat Autònoma de Barcelona Fundació Puigvert Barcelona Spain
EAU Guidelines Office Board European Association of Urology The Netherlands
References provided by Crossref.org
